Larissa de Mattos Oliveira

Larissa de Mattos Oliveira

Auto-generated profile, based on publicly available information

Larissa de Mattos Oliveira

Programa de Pós-Graduação em Biotecnologia, Universidade Estadual de Feira de Santana, Av. Transnordestina, s/n - Feira de Santana, Novo Horizonte - BA, 44036-900, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2018 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
JGJuliana Cecília de Carvalho Gallo
Juliana Cecília de Carvalho Gallo
LOLarissa de Mattos Oliveira
Larissa de Mattos Oliveira
JAJanay Stefany Carneiro Araújo
Janay Stefany Carneiro Araújo
ISIsis Bugia Santana
Isis Bugia Santana
MJManoelito Coelho dos Santos junior
Manoelito Coelho dos Santos junior

1 May 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
IRIsabella Mary Alves Reis
Isabella Mary Alves Reis
RCRodrigo Souza Conceição
Rodrigo Souza Conceição
RFRafael Short Ferreira
Rafael Short Ferreira
CSCleonice Creusa dos Santos
Cleonice Creusa dos Santos
GSGirliane Regina da Silva
Girliane Regina da Silva
ABAlexsandro Branco
Alexsandro Branco

16 October 2018 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
LOLarissa de Mattos Oliveira
Larissa de Mattos Oliveira
JAJanay Stefany Carneiro Araújo
Janay Stefany Carneiro Araújo
DJDavid Bacelar Costa Junior
David Bacelar Costa Junior
ISIsis Bugia Santana
Isis Bugia Santana
ADAngelo Amâncio Duarte
Angelo Amâncio Duarte
MJManoelito Coelho dos Santos junior
Manoelito Coelho dos Santos junior

1 February 2023 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MJManoelito Coelho dos Santos junior
Manoelito Coelho dos Santos junior
JAJanay Stefany Carneiro Araújo
Janay Stefany Carneiro Araújo
LOLarissa de Mattos Oliveira
Larissa de Mattos Oliveira
KAKaio Vinícius Freitas de Andrade
Kaio Vinícius Freitas de Andrade
RBRaquel Guimarães Benevides
Raquel Guimarães Benevides
FLFranco Leite
Franco Leite
Introduction: Diseases caused by protozoa are one of the leading causes of death world-wide, especially in tropical regions such as Brazil. Chagas disease, leishmaniasis, and malaria are responsible for around 234 million cases and more than 400,000 deaths worldwide. Despite this scenario, drugs for these diseases have several limitations, which justifies the search for new treat-ments. Iron superoxide dismutase is a promising target for the drug design to treat patients with these diseases. It is a validated target and protects against oxidative stress. Aim: Thus, this systematic review aimed to synthesize evidence on the importance of superoxide dismutase in the drug design to treat patients with this protozoosis. Method: A search was performed for in vitro and in vivo studies, without publication and language restrictions, in MEDLINE (PubMed), LILACS (BVS), Science Direct, and EMBASE (Elsevier). Studies that pointed to the relationship between the reduction or increase in superoxide dismutase activity and the diseases were included. 23 studies were selected for the qualitative synthesis. Result: The results showed that the inhibition or reduction of the enzyme activity decreases the de-gree of infection and reinfection and improves the results in treating these diseases. In contrast, the increase in activity caused a high degree of survival and resistance of the parasites. Conclusion: However, the overall quality of evidence is low and more studies with methodological rigor are provided.

31 July 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
IRIsabella Mary Alves Reis
Isabella Mary Alves Reis
GSGirliane Regina da Silva
Girliane Regina da Silva
LOLarissa de Mattos Oliveira
Larissa de Mattos Oliveira
MJManoelito Coelho dos Santos junior
Manoelito Coelho dos Santos junior
TSTania Maria Sarmento Silva
Tania Maria Sarmento Silva
ABAlexsandro Branco
Alexsandro Branco

1 July 2024 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
LOLarissa de Mattos Oliveira
Larissa de Mattos Oliveira
JAJanay Stefany Carneiro Araújo
Janay Stefany Carneiro Araújo
KAKaio Vinicius Freitas de Andrade
Kaio Vinicius Freitas de Andrade
AMAna Tereza Gomes Guerrero Moureau
Ana Tereza Gomes Guerrero Moureau
MJManoelito Coelho dos Santos junior
Manoelito Coelho dos Santos junior
Introduction: Chikungunya fever is a disease caused by infection with the Chikungunya virus, transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Despite its self-limited character, more than 60% of patients have chronic recurrent arthralgia with debilitating pain that lasts for years. Aim: The objective of this review was to gather and analyze evidence from the literature on potential therapeutic strategies with molecules from natural products for the treatment of Chikungunya fever. Methods: A search was performed for clinical trials, observational studies, in vitro or in vivo, without restriction of the year of publication or language in electronic databases (Medline/PubMed, EMBASE, Google Scholar, The Cochrane Library, LILACS (BVS), clinical trial registries (Clinical Trials.gov), digital libraries from CAPES theses and dissertations (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and conference abstracts. A quality assessment of the selected studies was performed using the SYRCLE, RoB2 and SciRAP tools. Results: 42 studies were included, which showed molecules with potential antiviral pharmacological activity or with activity in reducing the joint complications caused by CHIKV infection. Conclusions: Among the molecules found in the survey of references, regarding the class of secondary metabolites, flavonoids stood out and for this reason, the molecules may be promising candidates for future clinical trials. Overall, evidence from in vitro studies was of acceptable quality; in vivo and intervention studies showed a high risk of bias, which is a limitation of these studies.